Fresenius faces massive charges from probe into US business
This article was originally published in Clinica
Executive Summary
Dialysis company Fresenius Medical Care faces a "substantial and material charge" - between $200 million and $500 million by some estimates - in its third quarter, as the company settles investigations by the US government into business practices at its subsidiary National Medical Care (NMC).